Sunday November 22 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

UCB Pharma


Contact Details:
Chemin du Foriest
Braine l'Alleud
B-1420
Belgium
Tel:00 32 2 386 2111
Fax:00 32 2 386 2704
Email:
WWW:

www.ucb-pharma.com/




Recent Publications by UCB Pharma:

A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis.
The American College of Rheumatology (ACR) 20% preliminary definition of...
10th October, 2009
Pharmacometrics, Department of Global Exploratory Development, UCB Pharma Clin Pharmacol Ther. 2009 Oct;86(4):387-95. Epub 2009 Jul 22.
DOI Direct Link
The inhibitory avoidance test optimized for discovery of cognitive enhancers.
In the present article, we describe a new protocol for the inhibitory...
2nd October, 2009
CNS Pharmacology Department-Cognitive Psychopharmacology, UCB Pharma, Behav Res Methods. 2009 Aug;41(3):805-11.
DOI Direct Link
A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and implementation.
The 3rd American Association of Pharmaceutical Scientists (AAPS)/Food and...
25th September, 2009
UCB Pharma, Exploratory Statistics, Braine L'Alleud, Belgium. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 1;877(23):2235-43.
DOI Direct Link
Brivaracetam inhibits spreading depression in rat neocortical slices in vitro.
Epilepsy and migraine are episodic neurological disorders with marked...
11th September, 2009
UCB Pharma SA, CNS Research, Braine-l'Alleud, Belgium. Seizure. 2009 Jul;18(6):453-6. Epub 2009 Feb 10.
DOI Direct Link
Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.
Seletracetam is a pyrrolidone derivative with a one-log-unit higher...
26th August, 2009
CNS Research, UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l'Alleud, Eur J Pharmacol. 2009 Jul 1;614(1-3):30-7. Epub 2009 Apr 19.
DOI Direct Link

View more UCB Pharma research publications.

Press Releases on UCB Pharma:

BioPortfolio Logo
Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32 29th October, 2009 Mylan Inc.
-- On a GAAP basis, earnings per diluted share of $0.29 for the nine months ended September 30, 2009. Mylan's Chairman and CEO Robert J. Coury commented: "I am particularly
Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications 26th October, 2009 Reportlinker
NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Immunotherapies and Vaccines for Nontraditional
Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting 26th October, 2009 Shire plc
SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of three 5-aminosalicylic acid (5-ASA)
Novasep Gains SafeBridge(R) "Potent Compound Safety Certification" for its Le Mans Facility 17th September, 2009 Novasep
POMPEY, France, September 17 /PRNewswire/ -- Novasep is pleased to announce that its site in Le Mans - France, specialized in the development and manufacturing of Highly Potent Active
Novasep Acquires Bioprocess Development Specialist and Contract Manufacturer Henogen 6th July, 2009
POMPEY, France, July 6 /PRNewswire/ -- Novasep, a leading producer of active pharmaceutical ingredients (APIs) and purification technologies for the life science industries, announces today the

BioNews Results for UCB Pharma:

BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antibodies
NewsBlaze:  Nov 13 2009 10:55AM Matching: ucb pharma
Announcing the 9th Annual ePharma Summit February 8-10, 2010 Hyatt Regency at PennEURs Landing, Philadelphia
Pharma Live:  Nov 12 2009 12:04AM Matching: ucb pharma
Week of Nov. 9, 2009: Merck and Schering-Plough Begin Combined Operations; UCB Appoints VP; More
Indianapolis Recorder:  Nov 12 2009 1:28AM Matching: ucb pharma
Arthritis: Research from UCB Pharma S.A. has provided new information about arthritis
NewsRX:  Nov 11 2009 5:09AM Matching: ucb pharma
Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation
Yahoo! Canada:  Nov 11 2009 10:15PM Matching: ucb pharma
Promote your company here: BioNewsCast - Press Release Distribution

View more UCB Pharma news.

UCB Pharma Patents:

US Patent No.Title
7608694 Antibody molecules having specificity for human IL-1.beta.
7456286 Bicyclic heteroaromatic compounds as kinase inhibitors
7452976 Biological products
7419659 Expression control using variable intergenic sequences
7402662 Antibody molecules specific to human tumor necrosis factor alpha

View more UCB Pharma patents.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 14 individuals from UCB Pharma using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 6453 times since April 2007, the link to the organisation's website has been followed 836 times

Recent Search Terms used to find this page: ucb pharma | UCB pharma san diego | List of patent held by UCB pharma | ucb pharma 2009 | ucb pharma | UCB Pharma | ucb pharma | UCB Pharma | ucb pharma | ucb pharma | .

Search for more companies in Braine l'Alleud

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for UCB Pharma

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.